Bond.az White LogoBond.az Black Logo

Goldman Sachs Upgrades Segro: Price Target £9

Goldman Sachs upgrades Segro to Buy, lifts price target to £9. Strong letting momentum and data center strategy key.

Sarah Johnson
BySarah Johnson- Senior Editor
|
0

Bond.az - Goldman Sachs upgraded Segro PLC (LON:SGRO) from Neutral to Buy on Monday and raised its price target to £9.00 from £8.00, citing strong letting momentum despite rising vacancy rates in the UK logistics market.

The $13.25 billion market cap company has maintained dividend payments for 47 consecutive years. It delivered £23 million of new headline rent in Q1 2026 and captured 19% reversion, down from 36% in FY2025. Segro has approximately £49 million in reversion still to be captured by 2027.

Pre-letting activity was strong in Q4 2025, with Segro securing approximately £16 million, its strongest quarterly performance since Q1 2024. The company signed a further £12 million of pre-lets in Q1 2026, predominantly driven by data centre-related transactions. With a P/E ratio of 17.86 and revenue growth of 7.56%, Segro maintains a solid financial health.

Segro targets one to two fully fitted data centre developments per year, with Goldman Sachs maintaining capex assumptions at £725 million in 2027 and £775 million by 2028. The company’s EPRA cost ratio stood at 17.5% in FY2025.

The loan-to-value ratio stood at approximately 31% in Q1 2026, supported by £106 million of disposals completed during the quarter and a further £138 million exchanged expected to complete over the remainder of 2026. UBS recently downgraded Segro from Buy to Neutral but raised its price target from GBP8.15 to GBP8.40.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...